Prostate cancer incidence rates, trends, and treatment related to prostate-specific antigen screening recommendations in the United States

Changes in US prostate-specific antigen (PSA) screening guidelines have impacted prostate cancer (PCa) incidence rates and trends. This study shows corresponding changes in PCa incidence rates and describes treatment patterns by tumor stage, age, and race/ethnicity. Analyses were based on 777,152 ca...

Full description

Saved in:
Bibliographic Details
Published in:Cancer epidemiology 2024-12, Vol.93, p.102700, Article 102700
Main Author: Merrill, Ray M.
Format: Article
Language:English
Subjects:
Adenomatous polyposis coli
Age groups
Antigen-presenting cells
Antigens
Autopsy
Cancer incidence
Cancer screening
Cancer therapies
Chemotherapy
Clinical trials
Disease
Erectile dysfunction
Ethnicity
Medical screening
Minority & ethnic groups
Mortality
Patients
Population
Prostate cancer
Prostate-specific antigen
Public health
Race
Radiation
Surgery
Trends
Tumors
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Changes in US prostate-specific antigen (PSA) screening guidelines have impacted prostate cancer (PCa) incidence rates and trends. This study shows corresponding changes in PCa incidence rates and describes treatment patterns by tumor stage, age, and race/ethnicity. Analyses were based on 777,152 cases diagnosed in 17 population-based tumor registries in the SEER Program of the US National Cancer Institute, 2007–2021. Rates were age adjusted and trends assessed using annual percent change and joinpoint regression. PCa age-adjusted incidence rates (per 100,000) fell from 165.8 in 2007 to 101 in 2014 (APC=-6.51, p
ISSN:1877-7821
1877-783X
1877-783X
DOI:10.1016/j.canep.2024.102700